title: The pneumonia severity index predicts time to clinical stability in patients with community-acquired pneumonia.
abstract: METHODS
  A total of 33 hospitals in 13 countries in North America, Europe, Africa, Asia and Latin America.
  
  
  OBJECTIVE
  To investigate the relationship between the pneumonia severity index (PSI) and the time to clinical stability from intravenous to oral antibiotic therapy in hospitalized adult patients with community-acquired pneumonia (CAP).
  
  
  METHODS
  An international, retrospective, observational study of random adult patients meeting the definition of CAP between June 2001 and May 2004.
  
  
  RESULTS
  The risk class (RC) according to the PSI was calculated for all patients. The criteria to define when a patient is clinically stable were evaluated daily during the first 7 days of hospitalization in all patients. The mean time to clinical stability for 254 patients in RC I was 4.2 days, for 233 patients in RC II it was 3.9 days, for 395 patients in RC III it was 4.6 days, for 644 patients in RC IV it was 5.0 days and for 296 patients in RC V it was 6.0 days. Significant positive correlations were observed between RC and time to clinical stability (P < 0.0001).
  
  
  CONCLUSIONS
  The PSI is a tool that can be used to predict time to clinical stability (i.e., time to antimicrobial switch therapy) in hospitalized patients with CAP.
authors.affiliation: Division of Infectious Diseases, University of Louisville, Louisville, Kentucky 40292, USA. f.arnold@louisville.edu
authors.forename: F
authors.initials: F
authors.lastname: Arnold
authors.forename: A
authors.initials: A
authors.lastname: LaJoie
authors.forename: T
authors.initials: T
authors.lastname: Marrie
authors.forename: P
authors.initials: P
authors.lastname: Rossi
authors.forename: F
authors.initials: F
authors.lastname: Blasi
authors.forename: C
authors.initials: C
authors.lastname: Luna
authors.forename: P
authors.initials: P
authors.lastname: Fernandez
authors.forename: J
authors.initials: J
authors.lastname: Porras
authors.forename: K
authors.initials: K
authors.lastname: Weiss
authors.forename: C
authors.initials: C
authors.lastname: Feldman
authors.forename: E
authors.initials: E
authors.lastname: Rodríguez
authors.forename: G
authors.initials: G
authors.lastname: Levy
authors.forename: F
authors.initials: F
authors.lastname: Arteta
authors.forename: J
authors.initials: J
authors.lastname: Roig
authors.forename: J
authors.initials: J
authors.lastname: Rello
authors.forename: J
authors.initials: J
authors.lastname: Ramirez
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000473:pathology*; D006801:Humans; D011014:Pneumonia / Q000188:drug therapy / Q000473:pathology*; D012189:Retrospective Studies; D012720:Severity of Illness Index
chemical_list: D000900:Anti-Bacterial Agents